-
SLIDESHOW: Recent Data from LEO Pharma on Chronic Hand Eczema
16 Jun 2025 21:16 GMT
LEO Pharma has recently conducted several studies … , Germany. Poster presentation #27
3. LEO Pharma survey: Dermatology providers say chronic … .com/press-releases/leo-pharma-survey-dermatology-providers-say-chronic …
-
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)
03 Jun 2025 07:05 GMT
… first disease for which LEO Pharma will investigate delgocitinib … Bourdon, Chief Executive Officer, LEO Pharma. “PPP is a … plaque psoriasis.8
About LEO Pharma
LEO Pharma is a global leader … more information, visit www.leo-pharma.com.
References
Tanimoto A …
-
Communiqué 2025: celebrating excellence in healthcare communications
04 Jul 2025 12:09 GMT
… Anthem PR on behalf of LEO Pharma UK. The judges were impressed …
-
Three-month interim report (Q1) 2025 (Unaudited): LEO Pharma Delivers 9% Revenue Growth at Constant Exchange Rates and Doubles Adjusted EBITDA Margin to 16%
15 May 2025 07:15 GMT
… Additionally, in January, LEO Pharma announced a strategic partnership with … develop the foundations for LEO Pharma’s long-term … Christophe Bourdon, CEO of LEO Pharma.
Q1 2025 Financial overview
… )
N.m.
About LEO Pharma
LEO Pharma is a global leader in …
-
To Sharpen Focus on the Global Commercialization of Strategic Products and the External Partnership Model, LEO Pharma Makes Changes to Leadership
13 May 2025 11:30 GMT
… at LEO Pharma on June 1, 2025. Frederik joins LEO Pharma from … the significant restructuring of LEO Pharma during the past couple … amp; Corporate Affairs
About LEO Pharma
LEO Pharma is a global leader in … . Headquartered in Denmark, LEO Pharma has a team of …
-
LEO Pharma reports outcomes from Phase IIb trial of atopic dermatitis therapy
12 May 2025 22:17 GMT
… from baseline to week 16.
LEO Pharma Science, Search & … Jacob Pontoppidan Thyssen said: “LEO Pharma is committed to making … elevated in AD patients.
LEO Pharma and immunology company argenx … In May last year, LEO Pharma reported positive data from the …
-
LEO Pharma Announces Positive Preliminary Phase 2b Findings for Temtokibart in Atopic Dermatitis
09 May 2025 17:05 GMT
… ,” Jacob Pontoppidan Thyssen, PhD, DmSci, LEO Pharma chief scientific officer and EVP … the statement.
Pending final analysis, LEO Pharma expects to present full data … scientific meetings.1
References
1. LEO Pharma announces positive topline phase 2b …
-
LEO Pharma announces Positive Topline Phase 2b Results for Temtokibart in Moderate-to-Severe Atopic Dermatitis
09 May 2025 10:13 GMT
… underlies many skin conditions. LEO Pharma and argenx jointly developed temtokibart … develop and commercialize temtokibart.
LEO Pharma is currently collecting and evaluating … temtokibart from argenx.
About LEO Pharma
LEO Pharma is a global leader in …
-
LEO Pharma Announces Publication of Head-to-Head DELTA FORCE Study Results in The Lancet
24 Apr 2025 10:21 GMT
… the LEO Pharma team,” said Robert Spurr, EVP, LEO Pharma, North America and President, LEO Pharma … and the United States.
About LEO Pharma
LEO Pharma is a global leader in … more information, visit www.leo-pharma.com. LEO Pharma Canada is located in Toronto …
-
Improvement with Nemluvio for prurigo nodularis sustained up to 2 years, data show
03 Jul 2025 17:23 GMT
… , Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron …
About
© 1995-2025